Loading stock data…
SOPH
$5.40+0.12 (+2.27%)
After Hours$5.40+0.00 (+0.00%)· Last close Jun 9
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SOPHiA GENETICS SA in the Healthcare sector is trading at $5.40. Wall Street consensus targets $8.00 (3 analysts), implying a +48.1% move over the next 12 months. The stock is currently near its 52-week high of $5.70, remaining 17.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.40
Potential Downside
0%
Whystock Fair Value$5.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic mod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-177.15%
Volume
Today's trading volume
235,989
Recent News
Insider Spends US$99k Buying More Shares In SOPHiA GENETICS
Even if it's not a huge purchase, we think it was good to see that George Cardoza, the Executive VP & CFO of SOPHiA...
Undervalued Opportunities: Top Penny Stocks To Watch In May 2026
The United States market has shown notable resilience, with a 27% increase over the past year and a forecasted annual earnings growth of 17%. For investors looking beyond established giants, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Although the term may seem outdated, these stocks remain relevant by providing potential growth when supported by robust financial health.
SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary
Moby summary of SOPHiA GENETICS S.A.'s Q1 2026 earnings call
SOPHiA GENETICS Q1 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Revenue growth and re
SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript
In the first quarter, we delivered revenue growth of 22% year-over-year. In addition to processing more data volume than ever, we also achieved adjusted gross margin of 75.4%, demonstrating the unique scalability of our hyper-efficient analytics platform.